Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Fei Re Qing Granules
The First People's Hospital of Lianyungang
Severe Pneumonia Caused by Multidrug-resistant Gram-negative Bacterial Infection
1 trial -
Forced administration of furosemide
The First People's Hospital of Lianyungang
Cytoreductive Surgery
1 trial -
Fruquintinib and Everolimus
The First People's Hospital of Lianyungang
Renal Cell Carcinoma, Clear Cell, Somatic
1 trial -
G-CSF (Granulocyte colony-stimulating factor)
The First People's Hospital of Lianyungang
Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization
1 trial -
GD007 Low-dose drug group
The First People's Hospital of Lianyungang
Moderate-Severe Intrauterine Adhesions
1 trial -
GDMT
The First People's Hospital of Lianyungang
Heart Failure With Preserved Ejection Fraction
1 trial -
Gastrodin Injection
The First People's Hospital of Lianyungang
Sensorineural Hearing Loss
1 trial -
Gemcitabine, cisplatin
The First People's Hospital of Lianyungang
Bladder Cancer
1 trial -
Ginkgo Biloba Extract
The First People's Hospital of Lianyungang
Acute Ischemic Stroke
1 trial -
GnRH-a
The First People's Hospital of Lianyungang
Infertility, Female
1 trial -
GnRH-a
The First People's Hospital of Lianyungang
Clinical Pregnancy Rate
1 trial -
GnRH-a-1M
The First People's Hospital of Lianyungang
Adenomyosis of Uterus
1 trial -
GnRHa
The First People's Hospital of Lianyungang
Cesarean Scar Diverticula
1 trial -
Goserelin
The First People's Hospital of Lianyungang
Allogeneic Haematopoietic Stem Cell Transplantation
1 trial -
Guideline-directed medical therapy
The First People's Hospital of Lianyungang
Heart Failure With Reduced Ejection Fraction
1 trial -
HG204
The First People's Hospital of Lianyungang
MECP2 Duplication Syndrome
1 trial -
Health education and conservative management of clinical routines
The First People's Hospital of Lianyungang
Recurrent Acute Pancreatitis
1 trial -
HellenCare
The First People's Hospital of Lianyungang
Alzheimer's Disease Dementia
1 trial -
Heparin Sodium
The First People's Hospital of Lianyungang
Cerebral Aneurysm
1 trial -
High risk experimental group
The First People's Hospital of Lianyungang
Adolescent Idiopathic Scoliosis
1 trial -
High-dose vitamin D2 softgels
The First People's Hospital of Lianyungang
Chronic Kidney Disease 5D
1 trial -
Huang-long Zhi-xiao Granule
The First People's Hospital of Lianyungang
Asthma Chronic
1 trial -
Huangqi Guizhi Wuwu decoction
The First People's Hospital of Lianyungang
Diabetic Nephropathies
1 trial -
Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin
The First People's Hospital of Lianyungang
Hypertension
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources